11 Jan 2019 Governance

Leukaemia UK and Leuka have merged

We are delighted to announce that on 1 November Leuka and Leukaemia UK merged, bringing together two of the UK’s leading leukaemia and blood cancer charities to create one charity dedicated to innovative research and care for people affected by blood cancers. The two charities have joined forces under the name Leukaemia UK, uniting Leuka’s 37 years’ experience in ground-breaking medical research with Leukaemia UK’s four decades of pioneering care.

From research to care, the new charity will continue to put people affected by blood cancers at its heart. Together, Leukaemia UK aims to carry out even more world-class research and advances in care.

Leukaemia UK will be led jointly by Leuka’s CEO Olive Boles and Leukaemia UK’s CEO Angela Smith-Morgan. The charity’s new Chair of Trustees is Chris Corbin, current Chair of Leuka, who is supported by a Board including both Leuka and Leukaemia UK Trustees.

Related posts

Lymphoma: Understanding relapse and treatment resistance

11 January 2019

Lymphoma: Understanding relapse and treatment resistance

Dr Dinis Calado, The Francis Crick Institute and Project Grant Holder

A record year for Leukaemia UK London Marathon runners

21 September 2022

A record year for Leukaemia UK London Marathon runners

62 runners put their best feet forward for Leukaemia UK A record 62 runners are taking part in this year’s London marathon to help fund vital research into leukaemia diagnosis,…

Leukaemia UK appoints Ian McCafferty CBE as their new Chair of Trustees to support new strategy to stop leukaemia devastating lives

7 November 2022

Leukaemia UK appoints Ian McCafferty CBE as their new Chair of Trustees to support new strategy to stop leukaemia devastating lives

Ian McCafferty CBE will take up the role in January 2023, from current Chair of Trustees, Chris Corbin OBE, and will lead the charity as it continues to grow. Chris…

A new clinical trial announced

21 May 2020

A new clinical trial announced

A study into the impact of severe covid-19 infection on patients who receive stem cell transplants for blood cancers and blood disorders.